Waters Corporation reported third quarter 2026 results that exceeded expectations across all key financial metrics. Total revenue reached $1.767 billion, surpassing the $1.75 billion consensus, while adjusted earnings per share grew 21% year-over-year. The performance was characterized by double-digit growth in mass spectrometry instruments and strong consumables demand, leading management to raise full-year 2026 guidance for both revenue and earnings.
Key Highlights
- Organic constant currency revenue grew 10% in the quarter, reaching the high end of management's 8-10% guidance range.
- The Analytical Sciences Division delivered $703 million in revenue, driven by double-digit chemistry and instrument growth from robust replacement trends and GLP-1 related demand.
- Synergy capture from the Biosciences and Diagnostic Solutions integration is progressing ahead of schedule, with the acquired businesses contributing $896 million to total revenue.
- The company expanded its proteomics portfolio through the acquisition of MOBILion Systems, a pioneer in high-resolution ion mobility separation technology.